Literature DB >> 34231197

How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial.

Emily J Cicali1,2, Amanda L Elchynski1,2, Kelsey J Cook3,4, John T Houder5, Cameron D Thomas1,2, D Max Smith6,7, Amanda Elsey1, Julie A Johnson1,2, Larisa H Cavallari1,2, Kristin Wiisanen1,2.   

Abstract

CYP2D6 genotype is increasingly being integrated into practice to guide prescribing of certain medications. The CYP2D6 drug metabolizing enzyme is susceptible to inhibition by concomitant drugs, which can lead to a clinical phenotype that is different from the genotype-based phenotype, a process referred to as phenoconversion. Phenoconversion is highly prevalent but not widely integrated into practice because of either limited experience on how to integrate or lack of knowledge that it has occurred. We built a calculator tool to help clinicians integrate a standardized method of assessing CYP2D6 phenoconversion into practice. During tool-building, we identified several clinical factors that need to be considered when implementing CYP2D6 phenoconversion into clinical practice. This tutorial shares the steps that the University of Florida Health Precision Medicine Program took to build the calculator tool and identified clinical factors to consider when implementing CYP2D6 phenoconversion in clinical practice.
© 2021 The Authors. Clinical Pharmacology & Therapeutics © 2021 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34231197      PMCID: PMC8404400          DOI: 10.1002/cpt.2354

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.903


  39 in total

1.  The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.

Authors:  A Gaedigk; S D Simon; R E Pearce; L D Bradford; M J Kennedy; J S Leeder
Journal:  Clin Pharmacol Ther       Date:  2007-10-31       Impact factor: 6.875

Review 2.  Addressing phenoconversion: the Achilles' heel of personalized medicine.

Authors:  Rashmi R Shah; Robert L Smith
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

3.  Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.

Authors:  Sheldon H Preskorn; Cecelia P Kane; Kasia Lobello; Alice I Nichols; Rana Fayyad; Gina Buckley; Kristen Focht; Christine J Guico-Pabia
Journal:  J Clin Psychiatry       Date:  2013-03-13       Impact factor: 4.384

Review 4.  Interpretation of Cytochrome P-450 Inhibition and Induction Effects From Clinical Data: Current Standards and Recommendations for Implementation.

Authors:  Stephen M Stout; Carrie W Nemerovski; Daniel S Streetman; Melody Berg; Jamie Hoffman; Kayann Burke; Nina M Bemben; Stephen J Sklar
Journal:  Clin Pharmacol Ther       Date:  2020-06-20       Impact factor: 6.875

Review 5.  Complexities of CYP2D6 gene analysis and interpretation.

Authors:  Andrea Gaedigk
Journal:  Int Rev Psychiatry       Date:  2013-10

6.  A useful tool for drug interaction evaluation: the University of Washington Metabolism and Transport Drug Interaction Database.

Authors:  Houda Hachad; Isabelle Ragueneau-Majlessi; René H Levy
Journal:  Hum Genomics       Date:  2010-10       Impact factor: 4.639

7.  Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity.

Authors:  Rachel Dalton; Seung-Been Lee; Katrina G Claw; Bhagwat Prasad; Brian R Phillips; Danny D Shen; Lai Hong Wong; Mitch Fade; Matthew G McDonald; Maitreya J Dunham; Douglas M Fowler; Allan E Rettie; Erin Schuetz; Timothy A Thornton; Deborah A Nickerson; Andrea Gaedigk; Kenneth E Thummel; Erica L Woodahl
Journal:  Clin Transl Sci       Date:  2019-10-25       Impact factor: 4.689

8.  Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC).

Authors:  Kelly E Caudle; Henry M Dunnenberger; Robert R Freimuth; Josh F Peterson; Jonathan D Burlison; Michelle Whirl-Carrillo; Stuart A Scott; Heidi L Rehm; Marc S Williams; Teri E Klein; Mary V Relling; James M Hoffman
Journal:  Genet Med       Date:  2016-07-21       Impact factor: 8.822

Review 9.  A Review of the Important Role of CYP2D6 in Pharmacogenomics.

Authors:  Christopher Taylor; Ian Crosby; Vincent Yip; Peter Maguire; Munir Pirmohamed; Richard M Turner
Journal:  Genes (Basel)       Date:  2020-10-30       Impact factor: 4.096

10.  A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management.

Authors:  Julie A Johnson; Larisa H Cavallari; Cameron D Thomas; Hari K Parvataneni; Chancellor F Gray; Justin T Deen; Hernan A Prieto; Luis F Pulido; Amanda R Elsey; Erica N Elwood; Petr Starostik; Yan Gong; Roger B Fillingim
Journal:  Genet Med       Date:  2021-01-08       Impact factor: 8.822

View more
  7 in total

1.  Pharmacogenetics: A Precision Medicine Approach to Combatting the Opioid Epidemic.

Authors:  D Max Smith; James M Stevenson; Teresa T Ho; Christine M Formea; Roseann S Gammal; Larisa H Cavallari
Journal:  J Am Coll Clin Pharm       Date:  2021-12-19

2.  Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators.

Authors:  Larisa H Cavallari; Emily Cicali; Kristin Wiisanen; Roger B Fillingim; Hrishikesh Chakraborty; Rachel A Myers; Kathryn V Blake; Bolanle Asiyanbola; Jordan F Baye; Wesley H Bronson; Kelsey J Cook; Erica N Elwood; Chancellor F Gray; Yan Gong; Lindsay Hines; Joseph Kannry; Natalie Kucher; Sheryl Lynch; Khoa A Nguyen; Aniwaa Owusu Obeng; Victoria M Pratt; Hernan A Prieto; Michelle Ramos; Azita Sadeghpour; Rajbir Singh; Marc Rosenman; Petr Starostik; Cameron D Thomas; Emma Tillman; Paul R Dexter; Carol R Horowitz; Lori A Orlando; Josh F Peterson; Todd C Skaar; Sara L Van Driest; Simona Volpi; Deepak Voora; Hari K Parvataneni; Julie A Johnson
Journal:  Clin Transl Sci       Date:  2022-08-04       Impact factor: 4.438

3.  The importance of phenoconversion when using the CYP2D6 genotype in clinical practice.

Authors:  Emily J Cicali; Kristin Wiisanen
Journal:  Pharmacogenomics       Date:  2022-09-14       Impact factor: 2.638

Review 4.  Advancing Pharmacogenomics from Single-Gene to Preemptive Testing.

Authors:  Cyrine E Haidar; Kristine R Crews; James M Hoffman; Mary V Relling; Kelly E Caudle
Journal:  Annu Rev Genomics Hum Genet       Date:  2022-05-10       Impact factor: 9.340

5.  Multidisciplinary Consulting Team for Complicated Cases of Neurodevelopmental and Neurobehavioral Disorders: Assessing the Opportunities and Challenges of Integrating Pharmacogenomics into a Team Setting.

Authors:  Pritmohinder S Gill; Amanda L Elchynski; Patricia A Porter-Gill; Bradley G Goodson; Mary Ann Scott; Damon Lipinski; Amy Seay; Christina Kehn; Tonya Balmakund; G Bradley Schaefer
Journal:  J Pers Med       Date:  2022-04-08

6.  Sub-Analysis of CYP-GUIDES Data: Assessing the Prevalence and Impact of Drug-Gene Interactions in an Ethnically Diverse Cohort of Depressed Individuals.

Authors:  Rustin D Crutchley; Nicole Keuler
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

7.  Leveraging large observational studies to discover genetic determinants of drug concentrations: A proof-of-concept study.

Authors:  Maxime Meloche; Grégoire Leclair; Martin Jutras; Essaïd Oussaïd; Marie-Josée Gaulin; Ian Mongrain; David Busseuil; Jean-Claude Tardif; Marie-Pierre Dubé; Simon de Denus
Journal:  Clin Transl Sci       Date:  2022-02-05       Impact factor: 4.438

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.